Off-Label Use Should Be Restricted
Off-Label Use Should Be Restricted. Researchers are asking for stricter penalties and fines for those pharmaceutical companies that market drugs for "off label" promotion. According to both Adriane Fugh-Berman, M.D., an associate professor in the GUMC Department of Physiology and Biophysics, and Douglas Melnick, M.D., a … [Read more...] about Off-Label Use Should Be Restricted
Procrit, Aranesp, Epogen Restricted by FDA
Procrit, Aranesp, Epogen. Procrit, Aranesp and Epogen, anemia drugs used to treat chemotherapy patients, could soon have new restrictions imposed on them by the Food and Drug Administration (FDA). Late last week, the FDA announced a new black box warning for Procrit, Aranesp and Epogen regarding their association with shortened … [Read more...] about Procrit, Aranesp, Epogen Restricted by FDA
FDA Panels Urge Restricted Ketek Use
A pair of federal advisory committees has recommended against two of three existing uses for Ketek, an antibiotic from Sanofi-Aventis. The advisors say Ketek, approved by the Food and Drug Administration in April 2004, should be discontinued as a treatment for acute bacterial sinusitis and acute bacterial exacerbation of chronic … [Read more...] about FDA Panels Urge Restricted Ketek Use
Regulators Restrict Use of Drug
Regulators Recommend Restricted Use of Effexor. British regulators recommended on Monday that physicians restrict the use of the anti-depressant Effexor from drugmaker Wyeth because its use could have side effects for heart health and pose other potential risks that require more careful monitoring than other drugs in the … [Read more...] about Regulators Restrict Use of Drug
